One of the top fundraisers of 2024 is halving its workforce about a year after drawing in a $325 million series C. Cell therapy biotech Arsenal Biosciences has laid off about 50% of its staff as it ...

The Nature Index tracks primary research articles from 178 applied, health, natural and social sciences journals, across many different publishers, chosen by an independent group of researchers. The ...

The BIO campaign warns that decreased funding could hamper both current patient care and the future pipeline of medical breakthroughs. By featuring documentary-style stories of researchers and ...

The 10 most innovative biotech companies of 2025 are leveraging AI to find new drugs, match patients with the best treatments, and even support biodiversity research. This year’s list of biotech ...

This new book by the National Research Council recommends that the government expand existing regulations and rely on self-governance by scientists rather than adopt intrusive new policies. One key ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...

Danaher Corporation’s DHR Biotechnology segment continues to be a major contributor to its growth. In the first quarter of ...

The majority of Americans do not live in a biotech hub. Yet 62 percent of all U.S. biopharma venture investment occurs in Massachusetts and California, according to Pitchbook, while 77 percent of ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...